Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study

Table 1 Demographic and clinical characteristics of patients before propensity score matching

Patient demographic	All patients (n = 554)	Irinotecan group (n = 201)	Oxaliplatin group (n = 353)	P value
Age (yr)	57.1 ± 9.5	56.1 ± 9.6	57.7 ± 9.4	0.056
Sex ration (male:female)	193:361	62:139	131:222	0.137
Primary T stage				0.736
T1-2	64	22	42
T3-4	490	179	311
Primary N stage				0.036
N0	191	58	133
N1-2	363	143	220
Primary tumor location				0.613
Colon	322	114	208
Rectum	232	87	145
Primary tumor side				0.839
Right	75	28	47
Left	479	173	306
Timing of liver metastasis				< 0.001
Synchronous	482	157	325
Metachronous	72	44	28
Tumor number (median)	3 (1-10)	3 (1-9)	3 (1-10)	0.706
Tumor size (mm, mean ± SD)	27.6 ± 18.2	26.78 ± 17.2	29.0 ± 17.8	0.160
Localization of liver metastases				0.250
Unilobar	226	90	176
Bilobar	288	111	177
CEA level (ng/mL)	31.44 ± 85.3	24.93 ± 54.1	35.17 ± 98.65	0.175
CA 19-9 level (IU/mL)	215.4 ± 877.9	194.8 ± 232.8	227.4 ± 185.4	0.847
Extrahepatic metastasis				0.572
No	462	170	292
Yes	92	31	61
RAS mutation				0.174
Wildtype	332	128	204
Mutation	222	73	149
Biological agent				< 0.001
Cetuximab	118	57	61
Bevacizumab	187	97	90
No	249	47	202
Response				0.209
Complete response	5	0	5
Partial response	217	81	136
Stable disease	301	112	189
Progressive disease	31	8	23
Cycles	4 (1-16)	4 (1-12)	4 (1-16)	0.430
Concomitant ablation therapy	91	39	52	0.154
CRS
0-2	274	95	179
3-5	280	106	174
Resection				0.002
Simultaneous resection	145	41	104
Staged resection	409	160	249
Intraoperative blood loss (mL)	213 ± 198	204 ± 172	218 ± 212	0.437
Intraoperative RBC transfusion	24	10	14	0.289
Intraoperative RBC transfusion (U)	2 (1-12)	2 (1-6)	4 (2-12)	0.026
Operating time (min)	199 ± 74	190 ± 72	204 ± 76	0.039
Hepatic resection				0.357
Major resection	123	49	74
Minor resection	431	152	279
Margin status				0.308
Positive	72	30	42
Negative	482	171	311
Clavien-Dindo classification				0.057
I-II	164	53	111
II-V	32	7	25
Adjuvant chemotherapy				0.153
No	132	41	91
Yes	422	160	262

PSM: Propensity score matching; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; RBC: Red blood cell; CRS: Clinical risk score.